Inventaire - your friends and communities are your best library - Inventaire

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis

author

Bob Löwenberg

Johan Maertens

Harry Schouten

published in: The Lancet. Haematology.

date of publication: 2015-09-18

language: English

main subject: leukemia

Cites articles 27

Date

Title

Authors

2014-07-06

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Robert K Hills, Sylvie Chevret, Lucy Chilton, Anthony V. Moorman, Norbert Ifrah, Hervé Dombret, Frederick R. Appelbaum, Megan Othus, Stephen H Petersdorf, Elihu Estey
2014-11-27

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Markus G Manz, Jakob R. Passweg
2014-05-20

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

Noel Jean Milpied
2014-12-16

How I treat the older patient with acute myeloid leukemia

Bob Löwenberg
2013-09-12

Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status
2012-07-30

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Robert K Hills
2012-04-05

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Jean-Pierre Marolleau, Sylvie Chevret, Claude Preudhomme, Pierre Fenaux, Hervé Dombret, Cécile Pautas, Emmanuel Raffoux, Dominique Bordessoule, Oumedaly Reman, Sylvie Castaigne, Philippe Rousselot, Christine Terré, Pascal Turlure, Thierry de Revel, Nathalie Contentin, Acute Leukemia French Association
2012-09-17

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

Klaus H Metzeler, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Jessica Kohlschmidt, Nyla A Heerema, Deedra Rae Nicolet, Jonathan E Kolitz, Heiko Becker, Sebastian Schwind, Mark J Pettenati
2012-03-19

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

Claude Preudhomme
2012-09-04

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Martin Bornhäuser, Bob Löwenberg, Alois Gratwohl, Dietger Niederwieser
2011-06-21

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Kati Maharry, Martin S. Tallman, Hillard M. Lazarus, Richard A. Larson, David Rizzieri, Mark R Litzow, Daniel J Weisdorf, John DiPersio, Edward A Copelan, Luis Isola, Mitchell S Cairo, Waleska S Pérez, Donald Bunjes, Corey S Cutler, Olle Ringden, Robert J Soiffer
2011-03-01

Cytarabine dose for acute myeloid leukemia

Bob Löwenberg, Pieter Sonneveld, Alois Gratwohl, Johan Maertens, Harry Schouten
2010-01-26

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Hartmut Döhner, Bob Löwenberg, Pieter Sonneveld, Alois Gratwohl, Johan Maertens, Harry Schouten, Gregor Verhoef
2010-03-08

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

Robert Peter Gale, Sergio Giralt, Martin S. Tallman, Hillard M. Lazarus, Edmund K Waller, Daniel J Weisdorf, Luis Isola, Richard Maziarz, John DiPersio, Armand Keating, Theresa Hahn
2009-03-08

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

Robert K Hills, Anthony H. Goldstone
2009-09-01

High-dose daunorubicin in older patients with acute myeloid leukemia

Gregor Verhoef, Hartmut Döhner, Bob Löwenberg, Pieter Sonneveld, Alois Gratwohl, Johan Maertens, Harry Schouten
2009-06-01

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

Martha Wadleigh, Hartmut Döhner, Frederick R. Appelbaum, Joseph H Antin
2009-10-30

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Sergio Amadori, Richard A. Larson, Miguel A Sanz, Pierre Fenaux, Dietger Niederwieser, Clara D. Bloomfield, Frederick R. Appelbaum, Elihu Estey
2008-06-26

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison
2007-01-09

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Bob Löwenberg, Alois Gratwohl, Johan Maertens, Harry Schouten
2005-10-15

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Rainer Storb, Brenda M Sandmaier, Barry E Storer, David G. Maloney, Mohamed L Sorror
2002-08-01

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

Anthony H. Goldstone
2001-09-01

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

Anthony H. Goldstone
2001-06-01

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

Frederick R. Appelbaum, Judith A Shizuru, Rainer Storb, Mary E D Flowers, Beverly Torok-Storb
2001-09-01

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

Anthony H. Goldstone
1998-10-01

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

William Arcese
1983-11-01

Analysis of survival by tumor response.

Article - wd:Q40190632

Welcome to Inventaire

the library of your friends and communities

you are offline